Related Experiment Video

Updated: May 11, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Journey of the ALK-inhibitor CH5424802 to phase II clinical trial

Muhammad Latif1, Aamer Saeed, Seong Hwan Kim

  • 1Cancer and Infectious Disease Research Center, Division of Drug Discovery Research, Korea Research Institute of Chemical Technology, Daejeon, 305-600, Republic of Korea.

Archives of Pharmacal Research
|May 24, 2013
PubMed

Insights

The anaplastic lymphoma kinase (ALK) inhibitor CH5424802 demonstrates significant anti-tumor activity and tolerance in ALK-positive cancers. This promising drug shows potential for further clinical development as an effective anticancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is a key therapeutic target in human cancer.
  • Alterations in the ALK gene, including mutations and translocations, are implicated in cancer development.
  • Targeting ALK offers a promising strategy for cancer treatment.

Purpose of the Study:

  • To summarize recent advances on the anaplastic lymphoma kinase (ALK) inhibitor CH5424802 (AF802).
  • To review evidence supporting CH5424802's role as an ALK inhibitor.
  • To discuss the potential of CH5424802 for further clinical development.

Main Methods:

  • Review of preclinical data on CH5424802's efficacy and safety.
  • Analysis of CH5424802's kinase selectivity and pharmacokinetic profile.
  • Evaluation of anti-tumor activity in ALK-driven tumor models and mouse xenografts.

Main Results:

  • CH5424802 exhibits potent antiproliferative activity in various ALK-driven tumor models.
  • The drug demonstrates significant anti-tumor activity in mouse xenograft studies.
  • CH5424802 shows excellent tolerance and achieves tumor regression in preclinical settings.

Conclusions:

  • CH5424802 is a selective, second-generation anaplastic lymphoma kinase (ALK) inhibitor with a favorable pharmacokinetic profile.
  • The drug shows promising efficacy and safety, supporting its potential as an anticancer therapeutic.
  • Further clinical trials are warranted to evaluate CH5424802's full therapeutic potential in patients with ALK-positive cancers.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...